Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Business Wire
Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s discretion and subject to certain milestones, through March 31, 2026. The proceeds will be used to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes. Additional information on the agreement will be filed with t
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure Limited Q1 Earnings: Core Business Accelerating [Seeking Alpha]Seeking Alpha
- NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.MarketBeat
- NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at HC Wainwright from $24.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Novocure Reports First Quarter 2024 Financial ResultsBusiness Wire
- NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]Yahoo! Finance
NVCR
Earnings
- 5/2/24 - Beat
NVCR
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/22/24 - Form DEFA14A
- NVCR's page on the SEC website